Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Two type 1 diabetes patients are insulin-free after Eledon’s immunosuppressant and an islet transplant

Key Takeaway: Eledon has reported that two patients with type 1 diabetes have achieved insulin independence following treatment with its immunosuppressant and islet transplant. This breakthrough highlights the potential of Eledon's therapies to significantly improve the lives of individuals with diabetes. The success of these cases may pave the way for further advancements in diabetes treatment.
Price reaction · baseline $2.62 (2024-10-04 close) · 4 other ELDN headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Two patients with type 1 diabetes are now insulin-free.
  • Successful outcomes from Eledon's immunosuppressant and islet transplant.
  • Potential for transformative impact on diabetes treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What treatment led to insulin-free patients?

The treatment involved Eledon's immunosuppressant combined with an islet transplant.

How many patients achieved insulin independence?

Two patients with type 1 diabetes became insulin-free after the treatment.

What condition were the patients suffering from?

The patients were suffering from type 1 diabetes.

What is the significance of this treatment?

This treatment showcases the potential for transformative advancements in diabetes care.

Last updated: Oct 6, 2024